Brand & Product Security

Articles

Exploring how current and future legislation may impact the role of pharmacy benefit managers (PBMs).


What Will Change in the Pharma  Industry Look Like?

A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications. 

Does the Passing of a No Behavioral Health-Cost Sharing Law Have Any Bearing on Spending?

Conference’s opening session addresses the evolving landscape of healthcare coverage and accessibility.

Access USA 2024: The State of the Industry

Xhance is the first medication indicated for the treatment of chronic rhinosinusitis without nasal polyps to be approved by the FDA. 

FDA Approves Xhance, Optinose’s Treatment for Adults with Chronic Rhinosinusitis Without Nasal Polyps 

Approval was based on positive data from the Phase III MARCH study across a range of genetic progressive familial intrahepatic cholestasis types. 

FDA Expands Approval of Mirum’s Livmarli for Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

US Government Considers Banning Dealings with WuXi AppTec, Affiliates

IPX203—an oral formulation carbidopa/levodopa extended-release capsules —would expand Zambon’s neurology portfolio. 


 Amneal, Zambon Biotech Enter Exclusive European Licensing Agreement for Parkinson’s Disease Medication

Compared with piperacillin/tazobactam, Exblifep (cefepime/enmetazobactam) showed noninferiority and superiority in a clinical cure and microbiological eradication of complicated urinary tract infections.

FDA Approves Antibiotic Combination for Complicated Urinary Tract Infections 

Epkinly (epcoritamab-bysp), a subcutaneously administered, T-cell engaging, bispecific antibody, was previously granted Breakthrough Therapy Designation for the treatment of patients with relapsed or refractory follicular lymphoma following two or more prior lines of therapy.

FDA Grants Priority Review to Epkinly for Relapsed/Refractory Follicular Lymphoma 

Bayer's BAY 2927088 is under evaluation to treat unresectable or metastatic non-small cell lung cancer with tumors harboring activating HER2 mutations.

Legal & Regulatory